Arbutus Biopharma Corporation (ABUS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Arbutus Biopharma Corporation (ABUS) Healthcare & Pipeline Overview

Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. Its HBV product pipeline includes AB-729 and AB-836. The company has strategic alliances with multiple firms to advance its research and development programs, positioning it as a key player in the biotechnology sector.

What Is the Investment Thesis for ABUS?

The company's strategic collaborations and licensing agreements enhance its research and development capabilities. With a market capitalization of $1.01B, Arbutus operates in a high-growth sector driven by the need for effective HBV treatments. Key value drivers include successful clinical trial outcomes for AB-729 and AB-836, potential regulatory approvals, and expansion of its coronavirus antiviral programs. However, the company's negative profit margin of -237.9% and reliance on clinical trial success pose significant risks. Upcoming clinical trial results and potential partnerships represent near-term catalysts. The company's beta of 0.74 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

ABUS Key Highlights

Market Cap of $1.01B reflects investor valuation of Arbutus's pipeline and potential.

• Gross Margin of 36.2% indicates the profitability of Arbutus's revenue streams.
• Profit Margin of -237.9% highlights ongoing R&D investments and lack of product revenue.
• Beta of 0.74 suggests lower volatility compared to the broader market.
• Focus on HBV therapeutics addresses a significant unmet medical need with a large patient population.

Who Are ABUS's Competitors?

ABUS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ABUS's Key Strengths?

Proprietary RNAi technology platform.

• Strong intellectual property portfolio.
• Strategic alliances and collaborations.
• Experienced management team.

What Are ABUS's Weaknesses?

High dependence on clinical trial success.

• Negative profit margin.
• Limited product revenue.
• Small number of employees.

What Could Drive ABUS Stock Higher?

Clinical trial results for AB-729 in chronic HBV infection.

• Potential partnerships and licensing agreements for HBV and coronavirus therapeutics.
• Advancement of AB-836 and other pipeline candidates through preclinical and clinical development.
• Expansion of research and development efforts into new therapeutic areas.
• Regulatory approvals for HBV and coronavirus therapeutics.

What Are the Key Risks for ABUS?

Clinical trial failures for AB-729 and other pipeline candidates.

• Competition from other pharmaceutical and biotechnology companies.
• Regulatory hurdles and delays.
• High dependence on clinical trial success.
• Negative profit margin and limited product revenue.

What Are the Growth Opportunities for ABUS?

• Expansion of AB-729 Clinical Trials: Arbutus has the opportunity to expand the clinical trials for AB-729, its RNA interference therapeutic, into larger patient cohorts and different geographical regions. Positive results from these trials could lead to accelerated regulatory approval and market adoption. The global market for HBV therapeutics is substantial, with projections estimating continued growth due to the high prevalence of chronic HBV infection. Successful trials and subsequent commercialization could generate significant revenue streams for Arbutus.
• Advancement of AB-836 and Other Pipeline Candidates: Arbutus can drive growth by advancing its other pipeline candidates, such as AB-836, an oral capsid inhibitor, and AB-161, an oral HBV RNA destabilizer, through preclinical and clinical development. These programs target different mechanisms of action, potentially offering synergistic effects when combined with AB-729. The market for oral HBV therapies is expanding, driven by patient preference and ease of administration. Successful development and commercialization of these candidates could diversify Arbutus's revenue streams and enhance its market position.
• Strategic Collaborations and Licensing Agreements: Arbutus can leverage strategic collaborations and licensing agreements to expand its research and development capabilities and access new technologies. Collaborations with companies like Gritstone Oncology and Vaccitech provide access to complementary expertise and resources, accelerating the development of combination therapies. The market for collaborative drug development is growing, driven by the increasing complexity of drug discovery and development. Strategic partnerships can provide Arbutus with access to new markets and revenue streams.
• Development of Coronavirus Antiviral Medicines: Arbutus has the opportunity to develop small molecule antiviral medicines to treat coronaviruses, including COVID-19. The COVID-19 pandemic has highlighted the need for effective antiviral therapies. Arbutus's research and development programs in this area could lead to the discovery of novel antiviral agents with broad-spectrum activity. The market for antiviral drugs is substantial, with significant growth potential due to emerging infectious diseases. Successful development and commercialization of coronavirus antiviral medicines could generate significant revenue streams for Arbutus.
• Expansion into New Therapeutic Areas: Arbutus can explore opportunities to expand its research and development efforts into new therapeutic areas beyond HBV and coronaviruses. The company's expertise in RNA interference and antiviral drug development could be applied to other infectious diseases or chronic conditions. The market for novel therapeutics is constantly evolving, with new opportunities emerging as scientific understanding advances. Diversifying its therapeutic focus could reduce Arbutus's reliance on HBV and coronavirus markets and enhance its long-term growth prospects.

What Are ABUS's Competitive Advantages?

• Proprietary RNA interference (RNAi) technology platform for targeting hepatocytes.
• Strong intellectual property portfolio protecting its therapeutic candidates and technologies.
• Strategic alliances and collaborations with leading pharmaceutical and biotechnology companies.
• Expertise in HBV and coronavirus drug development.

What Does ABUS Do?

Arbutus Biopharma Corporation, founded as Tekmira Pharmaceuticals Corporation and rebranded in July 2015, is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. Headquartered in Warminster, Pennsylvania, Arbutus is focused on addressing the unmet needs of patients with chronic HBV infection. The company's HBV product pipeline features AB-729, a subcutaneously delivered RNA interference (RNAi) therapeutic candidate designed to target hepatocytes, inhibit viral replication, and reduce HBV antigens using N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently in Phase Ia/Ib clinical trials. Another key asset is AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. Arbutus's research and development programs also include AB-161, an oral HBV RNA destabilizer aimed at reducing HBsAg and other viral proteins, and AB-101, an oral PD-L1 inhibitor intended to reawaken patients' HBV-specific immune response. Additionally, the company is developing small molecule antiviral medicines to treat coronaviruses, including COVID-19. Arbutus has established strategic alliances, licensing agreements, and research collaborations with companies such as Talon Therapeutics, Inc., Gritstone Oncology, Inc., Alnylam Pharmaceuticals, Inc., Qilu Pharmaceuticals Co, Ltd., Assembly Biosciences, Inc., Acuitas Therapeutics, Inc., and Antios Therapeutics, Inc. The company also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination therapy including AB-729 for chronic HBV infection.

What Products and Services Does ABUS Offer?

• Develops novel therapeutics for chronic Hepatitis B virus (HBV) infection.
• Develops antiviral medicines to treat SARS-CoV-2 and other coronaviruses.
• Utilizes RNA interference (RNAi) technology to target hepatocytes and inhibit viral replication.
• Develops oral capsid inhibitors to suppress HBV DNA replication.
• Develops oral HBV RNA destabilizers to reduce HBsAg and other viral proteins.
• Develops oral PD-L1 inhibitors to reawaken patients' HBV-specific immune response.
• Engages in strategic alliances, licensing, and research collaborations with other companies.
• Conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates.

How Does ABUS Make Money?

• Develops and patents novel therapeutic candidates for HBV and coronaviruses.
• Out-licenses its technologies and therapeutic candidates to other companies for further development and commercialization.
• Generates revenue through research and development collaborations with other companies.
• Seeks regulatory approval for its therapeutic candidates and commercializes them directly or through partners.

What Industry Does ABUS Operate In?

Arbutus Biopharma operates within the competitive biotechnology industry, focusing on developing therapeutics for chronic Hepatitis B virus (HBV) infection and coronaviruses. The HBV market is driven by the need for more effective treatments, as current therapies often fail to achieve complete viral suppression. The global HBV therapeutics market is expected to grow, driven by increasing prevalence and improved diagnostics. Arbutus competes with companies developing antiviral therapies and immunomodulatory approaches. Key trends include the development of RNAi-based therapeutics and combination therapies. Arbutus's strategic collaborations and focus on novel mechanisms of action position it to capitalize on these trends.

Who Are ABUS's Key Customers?

• Pharmaceutical companies seeking to license or acquire novel HBV and coronavirus therapeutics.
• Patients with chronic Hepatitis B virus (HBV) infection.
• Healthcare providers who treat patients with HBV and coronaviruses.
• Government agencies and non-profit organizations involved in public health initiatives.

Over the past six months, Arbutus Biopharma Corporation insiders filed 2 SEC Form 4 transactions — 0 sales and 2 purchases. On net that is roughly 158K shares acquired (about $668K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Arbutus Biopharma Corporation

Revenue for Arbutus Biopharma Corporation came in at $1.0M during Q2 FY2026, a 99.4% contraction versus the preceding quarter. The company recorded a net loss of $5.1M, with diluted EPS of $-0.03. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ABUS averaged $0.20 in diluted EPS.

ABUS Valuation & Market Position

With a $1.01B market cap, Arbutus Biopharma Corporation sits in the small-cap segment of the market. Relative to its peer group, ABUS's quantitative score of 86/100 is above the peer average of 75/100.

Return on equity for Arbutus Biopharma Corporation stands at 129.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 58.0%, showing how much profit it generates from its asset base. ABUS trades at a trailing price-to-earnings ratio of 6.48, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 54.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 18.8%, the inverse of the P/E and a quick read on earnings relative to price.

Arbutus Biopharma Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 37.55 places it in the safe zone, indicating low near-term bankruptcy risk.

Arbutus Biopharma Corporation has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 396.0% above estimates on average.

Company Profile

Arbutus Biopharma Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Warminster, US. The company is led by CEO Lindsay Androski. ABUS has traded publicly since 2007.

ABUS Financials

ABUS Latest News

ABUS Analyst Consensus

ABUS MoonshotScore

What Investors Ask About Arbutus Biopharma Corporation (ABUS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources